Scarcell Therapeutics
Description
Scarcell Therapeutics is a french-based early clinical-stage biotechnology company pioneering the development of allogeneic cell therapy products with lead compound in Rheumatology and extended pipeline platform for selected chronic inflammatory, oncology, cardiovascular & dermatology conditions.
Scarcell Therapeutics is developing a cell therapy platform based on a novel approach using human Gingival Fibroblasts (hGF) that have unique tissue repair and restorative properties to address Rheumatoid arthritis conditions, a large unmet medical need with over 19 bn USD untapped market. Target product profile is a +2 Bn USD annual turnover therapy on the US & European markets.
Scarcell Therapeutics Investment Highlights are listed below:
• On track to be the first treatment to regenerate cartilage in patients suffering from osteoarthritis as existing treatments only provide relief and slow down the disease progression
• Exceptional healing properties evidenced in solid preclinical studies based on multiple animal models (horses, canines, rabbits, mice ; +800 animals injected) with no adverse results
• Straightforward and scalable bioproduction process with production costs much lower – by 10x to 300x - than other cell therapies considered to be the “gold standard”
• Advanced intellectual property with patent covering compositions for cell therapy in all therapeutic areas
• Ongoing development of a cell therapy platform to meet various unmet clinical needs, such as dermatology and cardiovascular diseases, with research at preclinical stage for some indications
Phase I will start in Q4 2024 in the UK leading hospitals including first-in-human clinical trials with an aim to observe efficacy data in healthy subjects, on top of standard safety and tolerability endpoints. Following Phase I, a Phase II clinical trial will be conducted in US & Europe with the ambition to reach large clinical outcomes within 24 months.
Scarcell Therapeutics is raising 27m USD to fuel its clinical and pre-clinical pipeline until their next inflection point in 2027.
Company members
Sarah Sorrel CEO
